Expertise in
3
conditions

Yanhua U. Ding

No. 71 Xinmin Street, 
Changchun, CN 
Expertise in
3
conditions
No. 71 Xinmin Street, 
Changchun, CN 

Overview

Yanhua Ding practices practicing medicine in Changchun, China.

Ding is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Hepatitis B, Hepatitis, Type 2 Diabetes (T2D), and Hepatitis C.

They are actively involved in clinical research, co-authoring 120 peer reviewed articles and participating in 6 clinical trials.

Locations

No. 71 Xinmin Street, Changchun, 130021, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1, Open-label, Randomized, Multiple-dose, Crossover Pharmacokinetic/Pharmacodynamic Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Phenotypes
A Phase 1, Open-label, Randomized, Multiple-dose, Crossover Pharmacokinetic/Pharmacodynamic Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Phenotypes
Enrollment Status: Completed
Publish Date: November 03, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Single-dose, Parallel Three-arm Comparative Study on Pharmacokinetics and Safety of BAT2506 Injection Versus the EU-licensed and US-licensed Simponi® in Healthy Chinese Male Subjects
A Randomized, Double-blind, Single-dose, Parallel Three-arm Comparative Study on Pharmacokinetics and Safety of BAT2506 Injection Versus the EU-licensed and US-licensed Simponi® in Healthy Chinese Male Subjects
Enrollment Status: Completed
Publish Date: August 28, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Phase I Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XKH001Injection in Healthy Adults
A Randomized, Double-Blind, Placebo-Controlled, Phase I Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XKH001Injection in Healthy Adults
Enrollment Status: Unknown
Publish Date: April 12, 2023
Intervention Type: Drug
Study Phase: Phase 1
Randomized, Double-blind, Dose-escalation, Placebo-controlled Single Administration Phase Ia Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics and Food Effects of VC005 Tablets in Healthy Subjects
Randomized, Double-blind, Dose-escalation, Placebo-controlled Single Administration Phase Ia Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics and Food Effects of VC005 Tablets in Healthy Subjects
Enrollment Status: Completed
Publish Date: September 02, 2022
Intervention Type: Drug
Study Phase: Phase 1
Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study
Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study
Enrollment Status: Completed
Publish Date: October 14, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults
A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults
Enrollment Status: Completed
Publish Date: October 16, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

120 Total Publications

Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling.
Pharmacokinetics, safety, and dose optimization of GST-HG171 in renal impairment: insights from physiologically based pharmacokinetic modeling.
Journal: Antimicrobial agents and chemotherapy
Published: July 15, 2026

Frequently Asked Questions about Yanhua U. Ding

Is Yanhua U. Ding a top-rated expert for Hepatitis B?

MediFind is an objective health platform that identifies experts based on real-world data. Yanhua U. Ding is classified as an Advanced expert for Hepatitis B, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yanhua U. Ding participate in research or clinical trials?

Yes. Yanhua U. Ding has published 120 articles and abstracts on conditions like Hepatitis B. You can view a list of Yanhua U. Ding's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ding's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile